Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01889238 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT01889238 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 118 participants.
The verdict
NCT01889238, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.
Interventions
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2013-06-12 |
| Est. Completion | 2024-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01889238
The ClinicalTrials.gov registry entry for NCT01889238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enzalutamide is the first listed.
NCT01889238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01889238 about?
NCT01889238 is a clinical study titled "Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer". The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.
What is the current status of trial NCT01889238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2013-06-12. Estimated completion is 2024-01-10.
What interventions are being tested in trial NCT01889238?
The interventions under investigation include: Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT01889238?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.